- Home
- JXG vs NERV Comparison
JXG vs NERV Comparison
Compare JXG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- NERV
- Stock Information
- Founded
- JXG N/A
- NERV 2007
- Country
- JXG China
- NERV United States
- Employees
- JXG N/A
- NERV N/A
- Industry
- JXG
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- NERV Health Care
- Exchange
- JXG Nasdaq
- NERV Nasdaq
- Market Cap
- JXG 16.9M
- NERV 14.6M
- IPO Year
- JXG N/A
- NERV 2014
- Fundamental
- Price
- JXG $0.51
- NERV $4.23
- Analyst Decision
- JXG
- NERV Hold
- Analyst Count
- JXG 0
- NERV 1
- Target Price
- JXG N/A
- NERV $4.00
- AVG Volume (30 Days)
- JXG 216.1K
- NERV 417.1K
- Earning Date
- JXG 12-05-2025
- NERV 11-05-2025
- Dividend Yield
- JXG N/A
- NERV N/A
- EPS Growth
- JXG N/A
- NERV N/A
- EPS
- JXG 0.35
- NERV N/A
- Revenue
- JXG $46,835,624.00
- NERV N/A
- Revenue This Year
- JXG N/A
- NERV N/A
- Revenue Next Year
- JXG N/A
- NERV N/A
- P/E Ratio
- JXG $1.52
- NERV N/A
- Revenue Growth
- JXG 21.68
- NERV N/A
- 52 Week Low
- JXG $0.48
- NERV $1.15
- 52 Week High
- JXG $6.12
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- JXG 25.18
- NERV 56.99
- Support Level
- JXG $0.55
- NERV $3.75
- Resistance Level
- JXG $0.59
- NERV $4.60
- Average True Range (ATR)
- JXG 0.06
- NERV 0.37
- MACD
- JXG -0.01
- NERV -0.04
- Stochastic Oscillator
- JXG 9.76
- NERV 64.55
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.